Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) Enterprise Value (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Enterprise Value for 8 consecutive years, with -$162.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value fell 159.66% to -$162.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$162.6 million, a 159.66% decrease, with the full-year FY2024 number at -$47.2 million, up 56.6% from a year prior.
  • Enterprise Value was -$162.6 million for Q3 2025 at Whitehawk Therapeutics, up from -$177.2 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$36.8 million in Q2 2021 to a low of -$231.1 million in Q1 2025.
  • A 5-year average of -$123.8 million and a median of -$129.8 million in 2022 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: plummeted 241.36% in 2021, then skyrocketed 56.6% in 2024.
  • Whitehawk Therapeutics' Enterprise Value stood at -$149.0 million in 2021, then fell by 15.82% to -$172.6 million in 2022, then surged by 36.92% to -$108.8 million in 2023, then surged by 56.6% to -$47.2 million in 2024, then plummeted by 244.22% to -$162.6 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Enterprise Value are -$162.6 million (Q3 2025), -$177.2 million (Q2 2025), and -$231.1 million (Q1 2025).